| Literature DB >> 34722940 |
Jesper Lindberg1,2,3, Thomas Björk-Eriksson3,4, Caroline E Olsson1,3.
Abstract
BACKGROUND ANDEntities:
Keywords: Capacity; LUR, Linac utilization rate; OIS, Oncology information system; Radiotherapy; Scheduling; Tool; Utilization
Year: 2021 PMID: 34722940 PMCID: PMC8531843 DOI: 10.1016/j.tipsro.2021.09.001
Source DB: PubMed Journal: Tech Innov Patient Support Radiat Oncol ISSN: 2405-6324
Scheduling categories.
| Category | Description |
|---|---|
| Pre-booked | Placeholder for patients following standardized care paths |
| Treatment | Patient treatment including undress/dress, positioning, image verification, beam delivery |
| Break | Staff breaks |
| Education | Education, seminars, etc. |
| Linac QA | Quality assurance on the linac or supporting devices |
| Maintenance | Maintenance or equipment downtime |
| Meetings | Staff meetings |
| Patient QA | Quality assurance of patients' treatment plans |
| Preparation | Time for staff to prepare for next patient (typically for stereotactic treatments) |
Definition of the variables used for calculations of linac utility rate (LUR).
| Linac opening hours | |
| Time for activities scheduled outside opening | |
| Time dedicated to patients' treatments during OH1 and OH2, no-shows excluded | |
| Time for non-treatment activities within opening hours | |
| Share of treatments during a day given in percent and calculated as LURT=(HT/OH1)*100 | |
| Share of non-treatments during a day given in percent and calculated as LURNT=(HNT/OH1)*100 | |
| Calculated as LUR = LURT + LURNT |
Total opening time for all linacs: 375 h per week, linacs 1–4 open 7:00 AM to 4:15 PM (9.25 h per day, 46.25 h per week) and linacs 5 to 8, 6:45 AM to 4:15 PM Monday to Friday (9.5 h per day, 47.5 h per week).
Planned (start of day) and observed rates (end of day) of linac utility rate, LUR (%) for a two-year period at the Sahlgrenska University Hospital in Sweden 2018–2020.
| Scheduled category | Mean ± SD [%] | Median (min─max) [%] | p-value | ||
|---|---|---|---|---|---|
| Planned | Observed | Planned | Observed | ||
| Treatment (LURT) | |||||
| Linac 1 | 56 ± 32 | 56 ± 32 | 63 (0─100) | 63 (0─100) | <0.01 |
| Linac 2 | 79 ± 26 | 79 ± 26 | 89 (0─110) | 88 (0─111) | <0.01 |
| Linac 3 | 31 ± 29 | 31 ± 29 | 25 (0─104) | 26 (0─101) | 0.31 |
| Linac 4 | 82 ± 22 | 80 ± 23 | 89 (0─109) | 87 (0─107) | <0.01 |
| Linac 5 | 92 ± 19 | 91 ± 19 | 95 (0─122) | 95 (0─127) | 0.06 |
| Linac 6 | 86 ± 23 | 85 ± 23 | 95 (0─127) | 93 (0─122) | <0.01 |
| Linac 7 | 88 ± 19 | 87 ± 20 | 93 (0─134) | 92 (0─133) | <0.01 |
| Linac 8 | 78 ± 27 | 76 ± 27 | 89 (0─149) | 88 (0─143) | <0.01 |
| Linac 1─4 | 77 ± 15 | 76 ± 15 | 77 (0─113) | 76 (0─109) | <0.01 |
| Linac 5─6 | 89 ± 14 | 88 ± 14 | 94 (0─112) | 92 (0─110) | <0.01 |
| Linac 7─8 | 83 ± 15 | 82 ± 15 | 89 (0─104) | 88 (0─106) | <0.01 |
| Total | 75 ± 11 | 74 ± 11 | 77 (0─97) | 75 (0─98) | <0.01 |
| Non-treatment (LURNT) | |||||
| Linac 1 | 11 ± 15 | 15 ± 19 | 6 (0─116) | 8 (0─116) | <0.01 |
| Linac 2 | 11 ± 17 | 14 ± 21 | 6 (4─116) | 6 (4─137) | <0.01 |
| Linac 3 | 10 ± 17 | 14 ± 19 | 6 (0─126) | 6 (2─129) | <0.01 |
| Linac 4 | 12 ± 19 | 14 ± 21 | 6 (0─116) | 6 (0─121) | <0.01 |
| Linac 5 | 10 ± 14 | 12 ± 15 | 6 (3─122) | 7 (3─122) | <0.01 |
| Linac 6 | 9 ± 12 | 11 ± 14 | 6 (0─122) | 7 (0─122) | <0.01 |
| Linac 7 | 11 ± 13 | 14 ± 15 | 8 (0─136) | 9 (0─136) | <0.01 |
| Linac 8 | 13 ± 17 | 17 ± 21 | 9 (0─122) | 10 (0─138) | <0.01 |
| Linac 1─4 | 13 ± 12 | 17 ± 14 | 8 (4─119) | 12 (4─119) | <0.01 |
| Linac 5─6 | 9 ± 9 | 12 ± 10 | 6 (1─65) | 8 (3─66) | <0.01 |
| Linac 7─8 | 12 ± 11 | 15 ± 13 | 9 (3─75) | 11 (2─75) | <0.01 |
| Total | 11 ± 6 | 14 ± 7 | 8 (5─64) | 11 (5─65) | <0.01 |
| LURT + LURNT | |||||
| Linac 1 | 68 ± 33 | 71 ± 34 | 78 (0─116) | 79 (0─163) | <0.01 |
| Linac 2 | 90 ± 25 | 92 ± 28 | 96 (5─189) | 96 (5─190) | <0.01 |
| Linac 3 | 40 ± 32 | 44 ± 33 | 35 (0─126) | 39 (3─134) | <0.01 |
| Linac 4 | 93 ± 17 | 94 ± 19 | 96 (0─204) | 96 (0─202) | <0.01 |
| Linac 5 | 101 ± 16 | 103 ± 16 | 103 (5─139) | 104 (5─216) | <0.01 |
| Linac 6 | 96 ± 21 | 96 ± 22 | 102 (0─134) | 101 (0─166) | <0.01 |
| Linac 7 | 99 ± 17 | 101 ± 18 | 102 (0─155) | 103 (0─172) | <0.01 |
| Linac 8 | 91 ± 24 | 93 ± 25 | 100 (0─163) | 100 (0─166) | <0.01 |
| Linac 1─4 | 90 ± 18 | 94 ± 20 | 90 (7─139) | 94 (7─155) | <0.01 |
| Linac 5─6 | 98 ± 13 | 100 ± 13 | 102 (3─132) | 102 (3─135) | <0.01 |
| Linac 7─8 | 95 ± 15 | 97 ± 16 | 100 (5─129) | 101 (5─154) | <0.01 |
| Total | 85 ± 11 | 88 ± 12 | 87 (16─109) | 89 (16─113) | <0.01 |
SD, Standard deviation; LURT, linac utility rates for treatment events; LURNT, linac utility rates for non-treatment events.
Comparison of median values between planned and observed calculated by Wilcoxon signed-rank test. A two-sided p-value ≤ 0.05 was considered to indicate statistical significance.
Fig. 1Linac utilization rate (LUR) changes per all eight linacs, the three linac groups and the whole machine park (positive/negative change is an increase/decrease in LUR between planned and observed scenarios). The histograms illustrate data at Day 0, according to scheduling categories of treatment, LURT and non-treatment, LURNT, and in total, Total LUR. Overall, 3390/1230/440 days (linacs/linac groups/machine park) were studied during the period 2018–2020.
Fig. 2Reasons for non-treatment linac utilization rate (LURNT) increases larger than 0% (top), 2% (middle) and 5% (bottom) during treatment days and their respective rate of occurrence. Data collected during a two-year period in 2018–2020, in total 3390 days were analyzed. Abbreviations: LinacQA, Quality assurance of linac; PatientQA, quality assurance of patients’ treatment plans.
Fig. 3Planned linac utilization rate (LUR) for present (Day 0) and forthcoming 100 weekdays (20 weeks) for the whole machine park, showing the mean values of all collections during the studied two-year period in 2018–2020. Data are shown for scheduling categories: treatment, LURT (a), non-treatment, LURNT (b) and in total, LUR (c). Error bars represent one standard deviation.